HPV Testing and Pap Test Market worth 4,523.1 M USD by 2020, According to a New Study on ASDReports

Tuesday 16 February 2016, Amsterdam

The report, now available on ASDReports, "HPV Testing & Pap Test Market by Test Type (HPV Testing (Follow-Up, Co-Testing, Primary)), by Application (Pap Test (Cervical Cancer, Vaginal Cancer)), by End User (Laboratories, Hospitals, Physicians’ Offices & Clinics) - Global Forecast to 2020", provides a detailed overview of the major drivers, restraints, opportunities, challenges, current market trends, and strategies impacting the market along with estimates and forecasts of revenue.

The HPV testing and Pap test Market is poised to reach USD 4,523.1 Million by 2020 from USD 3,287.4 Million in 2015, at a CAGR of 6.6% from 2015 to 2020.

A number of factors such as increasing number of cervical cancer cases, growing aging population, increasing awareness of cervical cancer screening programs, and government initiative and funding are propelling the growth of the HPV testing and Pap test market. However, changes in regulatory guidelines for cervical cancer screening and HPV vaccination are some major factors restraining the growth of this market. In addition to this, the uncertain reimbursement scenario serves to be a major challenge impacting the growth of the HPV test and Pap test market.

HPV testing and Pap test market has been divided into two major segments on basis of test type, namely, HPV testing and Pap test. Follow-up HPV testing, co-testing, HPV primary testing are three sub-segments of HPV testing. The Pap test segment is expected to account for the largest share of the HPV testing and Pap test market in 2015. HPV testing segment is expected to grow at the highest CAGR in the next five years. This fastest growth is attributed to the increasing incidences of cervical cancer, raising awareness of HPV screening, as well as the introduction of HPV primary test.

On the basis of type of application, the global HPV testing and Pap test market is classified into two major segments, namely, cervical cancer screening and vaginal cancer screening. The cervical cancer screening application segment is expected account for the largest share of the Pap test market in 2015. This large share can be attributed to the increasing incidences of cervical cancer and government initiatives to spread the awareness about cervical cancer screening.

HPV testing and Pap test market is classified into three segments on the basis of end users, namely, hospitals, laboratories, physicians’ offices and clinics. The laboratories end-user segment is expected account for the largest share of the HPV testing and Pap test market in 2015. Furthermore, the hospitals end-user segment is expected to grow at the highest CAGR in the next five years, as most of the diagnostic tests are carried out in-house in hospitals with advanced technologies in shorter period of time.

Abbott Laboratories (U.S.), Qiagen N.V. (The Netherlands), Hologic Inc. (U.S.), Roche Diagnostics (Switzerland), Quest Diagnostics (U.S.), Becton, Dickinson and Company (U.S.) are the key players operating in the HPV testing and Pap test market.